Clinical trial
Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
NCT02688881 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
- Lead sponsor
- Samsung Medical Center
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 5, 2017
- Completion date
- February 24, 2021
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
refractory solid tumors